Overview

Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, multi-center, parallel-group study designed to compare the safety and efficacy of a range of doses of ZP-Zolmitriptan intracutaneous microneedle systems to placebo.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Zosano Pharma Corporation
Zosano Pharma Inc.
Treatments:
Oxazolidinones
Zolmitriptan